Second-line avelumab in platinum-treated non-small cell lung cancer patients: comment on the JAVELIN Lung 200 clinical trial

Detalles Bibliográficos
Autores principales: Rocco, Danilo, Gravara, Luigi Della, Malapelle, Umberto, Troncone, Giancarlo, Gridelli, Cesare
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2019
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797646/
https://www.ncbi.nlm.nih.gov/pubmed/35117086
http://dx.doi.org/10.21037/tcr.2018.12.14
_version_ 1784641601827504128
author Rocco, Danilo
Gravara, Luigi Della
Malapelle, Umberto
Troncone, Giancarlo
Gridelli, Cesare
author_facet Rocco, Danilo
Gravara, Luigi Della
Malapelle, Umberto
Troncone, Giancarlo
Gridelli, Cesare
author_sort Rocco, Danilo
collection PubMed
description
format Online
Article
Text
id pubmed-8797646
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-87976462022-02-02 Second-line avelumab in platinum-treated non-small cell lung cancer patients: comment on the JAVELIN Lung 200 clinical trial Rocco, Danilo Gravara, Luigi Della Malapelle, Umberto Troncone, Giancarlo Gridelli, Cesare Transl Cancer Res Editorial AME Publishing Company 2019-03 /pmc/articles/PMC8797646/ /pubmed/35117086 http://dx.doi.org/10.21037/tcr.2018.12.14 Text en 2019 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Editorial
Rocco, Danilo
Gravara, Luigi Della
Malapelle, Umberto
Troncone, Giancarlo
Gridelli, Cesare
Second-line avelumab in platinum-treated non-small cell lung cancer patients: comment on the JAVELIN Lung 200 clinical trial
title Second-line avelumab in platinum-treated non-small cell lung cancer patients: comment on the JAVELIN Lung 200 clinical trial
title_full Second-line avelumab in platinum-treated non-small cell lung cancer patients: comment on the JAVELIN Lung 200 clinical trial
title_fullStr Second-line avelumab in platinum-treated non-small cell lung cancer patients: comment on the JAVELIN Lung 200 clinical trial
title_full_unstemmed Second-line avelumab in platinum-treated non-small cell lung cancer patients: comment on the JAVELIN Lung 200 clinical trial
title_short Second-line avelumab in platinum-treated non-small cell lung cancer patients: comment on the JAVELIN Lung 200 clinical trial
title_sort second-line avelumab in platinum-treated non-small cell lung cancer patients: comment on the javelin lung 200 clinical trial
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797646/
https://www.ncbi.nlm.nih.gov/pubmed/35117086
http://dx.doi.org/10.21037/tcr.2018.12.14
work_keys_str_mv AT roccodanilo secondlineavelumabinplatinumtreatednonsmallcelllungcancerpatientscommentonthejavelinlung200clinicaltrial
AT gravaraluigidella secondlineavelumabinplatinumtreatednonsmallcelllungcancerpatientscommentonthejavelinlung200clinicaltrial
AT malapelleumberto secondlineavelumabinplatinumtreatednonsmallcelllungcancerpatientscommentonthejavelinlung200clinicaltrial
AT tronconegiancarlo secondlineavelumabinplatinumtreatednonsmallcelllungcancerpatientscommentonthejavelinlung200clinicaltrial
AT gridellicesare secondlineavelumabinplatinumtreatednonsmallcelllungcancerpatientscommentonthejavelinlung200clinicaltrial

Ejemplares similares